Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Role of Serum Secretoneurin Levels in Patients with Traumatic Brain Injury

Author(s): Muhammet Faruk Akyüz, Murat Yücel, İremgül Güngör, Metin Yadigaroğlu, Selim Görgün, Hüseyin Karataş and Murat Güzel*

Volume 19, Issue 4, 2022

Published on: 08 November, 2022

Page: [383 - 390] Pages: 8

DOI: 10.2174/1567202620666221024112631

Price: $65

Abstract

Background: Secretoneurin is a neuropeptide expressed from endocrine, neuroendocrine, and neural tissues. Our study aimed to investigate whether there was a relationship between secretoneurin levels and the severity of traumatic brain injury (TBI).

Methods: Ninety patients aged over 18 years who were admitted to the emergency department with head trauma between April 2020 and October 2020 and 20 healthy volunteers (control group) were included in the study. Patients were divided into three groups according to Glasgow Coma Scale scores: Mild TBI (n=33), moderate TBI (n=28), and severe TBI (n=29). The final status of the patients was evaluated in three groups: exitus, discharge with Glasgow Outcome Scale (GOS) ≤ 3 and discharge with GOS >3.

Results: The median secretoneurin levels of patients with severe TBI 31.71 (14.21-70.95) were found to be significantly higher than in those with moderate TBI [17.30 (10.71-69.27) (P=0.025), and patients with moderate TBI had a substantially higher level of secretoneurin than those with mild TBI 11.70 (6-16.25) (P<0.001). There was no statistically significant difference between the median secretoneurin levels in patients with mild TBI and the control group 10.73 (5.33-13.18) (P=0.999). The secretoneurin cut-off value of >18.13 ng/mL had a sensitivity of 83.87% and a specificity of 77.97% for poor neurologic outcomes (AUC 0.86, 95% CI: 0.77- 0.92). The secretoneurin cut-off value of >20.67 ng/mL had a sensitivity of 90.91% and a specificity of 74.68% for mortality (AUC 0.85, 95% CI: 0.76-0.92).

Conclusion: Secretoneurin can be a useful biomarker in diagnosing patients with moderate-tosevere TBI. It may also guide physicians in predicting the clinical outcome of patients with TBI.

« Previous Next »
[1]
Algattas H, Huang J. Traumatic brain injury pathophysiology and treatments: Early, intermediate, and late phases post-injury. Int J Mol Sci 2013; 15(1): 309-41.
[http://dx.doi.org/10.3390/ijms15010309] [PMID: 24381049]
[2]
Dang B, Chen W, He W, Chen G. Rehabilitation treatment and progress of traumatic brain injury dysfunction. Neural Plast 2017; 2017: 1582182.
[http://dx.doi.org/10.1155/2017/1582182] [PMID: 28491478]
[3]
Dutton RP, Stansbury LG, Leone S, Kramer E, Hess JR, Scalea TM. Trauma mortality in mature trauma systems: Are we doing better? An analysis of trauma mortality patterns, 1997-2008. J Trauma 2010; 69(3): 620-6.
[http://dx.doi.org/10.1097/TA.0b013e3181bbfe2a] [PMID: 20093983]
[4]
Faul M, Coronado V. Epidemiology of traumatic brain injury. Handb Clin Neurol 2015; 127: 3-13.
[http://dx.doi.org/10.1016/B978-0-444-52892-6.00001-5] [PMID: 25702206]
[5]
Brazinova A, Rehorcikova V, Taylor MS, et al. Epidemiology of traumatic brain injury in Europe: A living systematic review. J Neurotrauma 2021; 38(10): 1411-40.
[http://dx.doi.org/10.1089/neu.2015.4126] [PMID: 26537996]
[6]
Lu J, Marmarou A, Choi S, et al. Mortality from traumatic brain injury. Acta Neurochir Suppl 2005; 95: 281-5.
[7]
Rault F, Terrier L, Leclerc A, et al. Decreased number of deaths related to severe traumatic brain injury in intensive care unit during the first lockdown in Normandy: At least one positive side effect of the COVID-19 pandemic. Acta Neurochir (Wien) 2021; 163(7): 1829-36.
[http://dx.doi.org/10.1007/s00701-021-04831-1] [PMID: 33813617]
[8]
Peeters W, van den Brande R, Polinder S, et al. Epidemiology of traumatic brain injury in Europe. Acta Neurochir (Wien) 2015; 157(10): 1683-96.
[http://dx.doi.org/10.1007/s00701-015-2512-7] [PMID: 26269030]
[9]
Majdan M, Plancikova D, Brazinova A, et al. Epidemiology of traumatic brain injuries in Europe: A cross-sectional analysis. Lancet Public Health 2016; 1(2): e76-83.
[http://dx.doi.org/10.1016/S2468-2667(16)30017-2] [PMID: 29253420]
[10]
Edwards SL. Using the Glasgow Coma Scale: Analysis and limitations. Br J Nurs 2001; 10(2): 92-101.
[http://dx.doi.org/10.12968/bjon.2001.10.2.5391] [PMID: 12170506]
[11]
Matis G, Birbilis T. The Glasgow Coma Scale-a brief review. Past, present, future. Acta Neurol Belg 2008; 108(3): 75-89.
[PMID: 19115670]
[12]
Hosseini SH, Ayyasi M, Akbari H, Heidari Gorji MA. Comparison of glasgow coma scale, Full outline of unresponsiveness and acute physiology and chronic health evaluation in prediction of mortality rate among patients with traumatic brain injury admitted to intensive care unit. Anesth Pain Med 2016; 7(5): e33653.
[http://dx.doi.org/10.5812/aapm.33653] [PMID: 29696116]
[13]
Zhao E, Hu H, Trudeau VL. Secretoneurin as a hormone regulator in the pituitary. Regul Pept 2010; 165(1): 117-22.
[http://dx.doi.org/10.1016/j.regpep.2009.11.019] [PMID: 20006654]
[14]
Trudeau VL, Martyniuk CJ, Zhao E, et al. Is secretoneurin a new hormone? Gen Comp Endocrinol 2012; 175(1): 10-8.
[http://dx.doi.org/10.1016/j.ygcen.2011.10.008] [PMID: 22036841]
[15]
Fischer-Colbrie R, Laslop A, Kirchmair R, Secretogranin II, Secretogranin II. Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995; 46(1): 49-70.
[http://dx.doi.org/10.1016/0301-0082(94)00060-U] [PMID: 7568909]
[16]
Mattsson N, Rüetschi U, Podust VN, et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 2007; 103(5): 1932-9.
[http://dx.doi.org/10.1111/j.1471-4159.2007.04985.x] [PMID: 17953655]
[17]
Miller C, Kirchmair R, Troger J, et al. CSF of neuroleptic-naive first-episode schizophrenic patients: Levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 1996; 39(11): 911-8.
[http://dx.doi.org/10.1016/0006-3223(95)00098-4] [PMID: 9162202]
[18]
Eder U, Leitner B, Kirchmair R, et al. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. Journal of neural transmission (Vienna, Austria: 1996) 1998; 105(1): 39-51.
[19]
Hasslacher J, Lehner GF, Harler U, et al. Secretoneurin as a marker for hypoxic brain injury after cardiopulmonary resuscitation. Intensive Care Med 2014; 40(10): 1518-27.
[http://dx.doi.org/10.1007/s00134-014-3423-4] [PMID: 25138227]
[20]
Wechselberger K, Schmid A, Posod A, et al. Secretoneurin serum levels in healthy term neonates and neonates with hypoxic-ischaemic encephalopathy. Neonatology 2016; 110(1): 14-20.
[http://dx.doi.org/10.1159/000444245] [PMID: 26968040]
[21]
Perrin PB, Niemeier JP, Mougeot JL, et al. Measures of injury severity and prediction of acute traumatic brain injury outcomes. J Head Trauma Rehabil 2015; 30(2): 136-42.
[http://dx.doi.org/10.1097/HTR.0000000000000026] [PMID: 24590151]
[22]
Assefa F, Lim J, Kim JA, et al. Secretoneurin, a neuropeptide, enhances bone regeneration in a mouse calvarial bone defect model. Tissue Eng Regen Med 2021; 18(2): 315-24.
[http://dx.doi.org/10.1007/s13770-020-00304-1] [PMID: 33145742]
[23]
Shyu WC, Lin SZ, Chiang MF, et al. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest 2008; 118(1): 133-48.
[http://dx.doi.org/10.1172/JCI32723] [PMID: 18079966]
[24]
Martí E, Ferrer I, Blasi J. Differential regulation of chromogranin A, chromogranin B and secretoneurin protein expression after transient forebrain ischemia in the gerbil. Acta Neuropathol 2001; 101(2): 159-66.
[http://dx.doi.org/10.1007/s004010000280] [PMID: 11271371]
[25]
Posod A, Wechselberger K, Stanika RI, et al. Administration of secretoneurin is protective in hypoxic–ischemic neonatal brain injury predominantly in the hypoxic-only hemisphere. Neuroscience 2017; 352: 88-96.
[http://dx.doi.org/10.1016/j.neuroscience.2017.03.055] [PMID: 28391015]
[26]
Hasslacher J, Ulmer H, Lehner G, et al. Postresuscitation care and prognostication after cardiac arrest—Does sex matter? Wien Klin Wochenschr 2022; 134(17-18): 617-25.
[http://dx.doi.org/10.1007/s00508-022-02026-x] [PMID: 35380262]
[27]
Posod A, Wechselberger K, Schmid A, et al. Excitotoxicity alters endogenous secretoneurin plasma levels, but supplementation with secretoneurin does not protect against excitotoxic neonatal brain injury. Neuroscience 2019; 410: 239-53.
[http://dx.doi.org/10.1016/j.neuroscience.2019.05.023] [PMID: 31121260]
[28]
Ng SY, Lee AYW. Traumatic brain injuries: Pathophysiology and potential therapeutic targets. Front Cell Neurosci 2019; 13: 528.
[http://dx.doi.org/10.3389/fncel.2019.00528] [PMID: 31827423]
[29]
Saadat S, Akbari H, Khorramirouz R, Mofid R, Rahimi Movaghar V. Determinants of mortality in patients with traumatic brain injury. Ulus Travma Acil Cerrahi Derg 2012; 18(3): 219-24.
[http://dx.doi.org/10.5505/tjtes.2012.03453] [PMID: 22864713]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy